<code id='43E44869C0'></code><style id='43E44869C0'></style>
    • <acronym id='43E44869C0'></acronym>
      <center id='43E44869C0'><center id='43E44869C0'><tfoot id='43E44869C0'></tfoot></center><abbr id='43E44869C0'><dir id='43E44869C0'><tfoot id='43E44869C0'></tfoot><noframes id='43E44869C0'>

    • <optgroup id='43E44869C0'><strike id='43E44869C0'><sup id='43E44869C0'></sup></strike><code id='43E44869C0'></code></optgroup>
        1. <b id='43E44869C0'><label id='43E44869C0'><select id='43E44869C0'><dt id='43E44869C0'><span id='43E44869C0'></span></dt></select></label></b><u id='43E44869C0'></u>
          <i id='43E44869C0'><strike id='43E44869C0'><tt id='43E44869C0'><pre id='43E44869C0'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:explore    - browse:29
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment